Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

STAT3 regulates the growth and immunoglobulin production of BCL(1) B cell lymphoma through control of cell cycle progression.

Karras JG, McKay RA, Lu T, Pych J, Frank DA, Rothstein TL, Monia BP.

Cell Immunol. 2000 Jun 15;202(2):124-35.

PMID:
10896772
2.

Stat3 as an oncogene.

Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr.

Cell. 1999 Aug 6;98(3):295-303. Erratum in: Cell 1999 Oct 15;99(2):239.

3.
4.

Protein tyrosine kinase inhibitors as novel therapeutic agents.

Levitzki A.

Pharmacol Ther. 1999 May-Jun;82(2-3):231-9. Review.

PMID:
10454200
5.

Cytokine signaling for proliferation, survival, and death in hematopoietic cells.

Miyajima A, Ito Y, Kinoshita T.

Int J Hematol. 1999 Apr;69(3):137-46. Review.

PMID:
10222650
6.
7.

Design of conditionally active STATs: insights into STAT activation and gene regulatory function.

Milocco LH, Haslam JA, Rosen J, Seidel HM.

Mol Cell Biol. 1999 Apr;19(4):2913-20.

8.

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.

Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, Dalton WS, Jove R.

Immunity. 1999 Jan;10(1):105-15.

9.
10.

STAT5 interaction with the T cell receptor complex and stimulation of T cell proliferation.

Welte T, Leitenberg D, Dittel BN, al-Ramadi BK, Xie B, Chin YE, Janeway CA Jr, Bothwell AL, Bottomly K, Fu XY.

Science. 1999 Jan 8;283(5399):222-5.

11.

Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia.

Lamy T, Liu JH, Landowski TH, Dalton WS, Loughran TP Jr.

Blood. 1998 Dec 15;92(12):4771-7.

12.

Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro.

Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, Tweardy DJ.

J Clin Invest. 1998 Oct 1;102(7):1385-92.

13.

IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis.

Ferlin-Bezombes M, Jourdan M, Liautard J, Brochier J, Rossi JF, Klein B.

J Immunol. 1998 Sep 15;161(6):2692-9.

14.

Mutagenesis of the BH3 domain of BAX identifies residues critical for dimerization and killing.

Wang K, Gross A, Waksman G, Korsmeyer SJ.

Mol Cell Biol. 1998 Oct;18(10):6083-9.

16.

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L.

Biochem J. 1998 Sep 1;334 ( Pt 2):297-314. Review.

17.

mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response.

Chao JR, Wang JM, Lee SF, Peng HW, Lin YH, Chou CH, Li JC, Huang HM, Chou CK, Kuo ML, Yen JJ, Yang-Yen HF.

Mol Cell Biol. 1998 Aug;18(8):4883-98.

18.

Activation of STAT transcription factors in oncogenic tyrosine kinase signaling.

Garcia R, Jove R.

J Biomed Sci. 1998;5(2):79-85. Review.

PMID:
9662066
19.

JAK/STAT signaling by cytokine receptors.

Liu KD, Gaffen SL, Goldsmith MA.

Curr Opin Immunol. 1998 Jun;10(3):271-8. Review.

PMID:
9638363
20.

Epitope mapping of HTLV envelope seroreactivity in LGL leukaemia.

Loughran TP Jr, Hadlock KG, Perzova R, Gentile TC, Yang Q, Foung SK, Poiesz BJ.

Br J Haematol. 1998 May;101(2):318-24.

PMID:
9609528

Supplemental Content

Support Center